Business Context and Reporting Period
This Form 8-K Current Report, dated August 28, 2024, pertains to Lifecore Biomedical, Inc. (NASDAQ: LFCR). The filing announces a significant executive leadership transition involving the appointment of a new Chief Financial Officer (CFO) and Secretary, effective September 3, 2024, and the concurrent departure of the incumbent CFO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Departure: John D. Morberg will cease serving as CFO and Secretary on September 2, 2024. His separation is classified as a termination without Cause subsequent to a Change in Control under his existing employment agreement.
- Executive Appointment: Ryan D. Lake has been appointed as the new CFO and Secretary, effective September 3, 2024. Mr. Lake previously served as CFO of Societal CDMO, Inc. (formerly Recro Pharma, Inc.) and Baudax Bio, Inc.
- Compensation Structure: Mr. Lake's employment agreement includes an annual base salary of $470,000 and eligibility for an annual incentive plan with a target bonus of 60% of base salary starting in fiscal year 2025.
- Equity Awards: As an inducement for employment, Mr. Lake will receive:
- 262,500 Restricted Stock Units (RSUs), vesting in five equal annual tranches of 52,500 shares.
- Up to 750,000 Performance Stock Units (PSUs), with terms consistent with prior awards granted to Paul Josephs.
- Severance Benefits: Mr. Lake is eligible for Tier 2 benefits under the Executive Change in Control Severance Plan upon a "Qualifying Termination." He is also entitled to 12 months of senior executive outplacement services if terminated without Cause or due to a material breach by the Company.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the transition of financial leadership and the associated compensation obligations. The equity awards were granted under the Company's Equity Inducement Plan adopted on March 20, 2024, relying on Section 4(a)(2) of the Securities Act of 1933 for exemption from registration.
Investor Verification Checklist
- Verify the exact vesting schedule and performance criteria for the 750,000 PSUs granted to Mr. Lake by reviewing the referenced Performance Stock Unit Award Agreement.
- Confirm the specific financial implications of Mr. Morberg's termination, including any severance payments due under his "Change in Control" agreement.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed terms regarding non-solicitation, confidentiality, and indemnification.
- Monitor future filings for the impact of the leadership transition on the Company's financial reporting and strategic direction.